Lunit Showcases AI-Powered Cancer Ecosystem at APEC High-Level Meeting on Health and the Economy and World Bio Summit 2025
Lunit highlights global leadership in cancer AI alongside world health experts with dedicated APEC HLMHE session and WBS 2025 Leaders' Dialogue SEOUL, South Korea, Sept. 16, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced its participation in two major global health gatherings taking...
Over 100 Healthcare Professionals Convene to Explore the Critical Impact of Early Nutrition on Long-Term Brain Development
Mead Johnson Clinical Study Reveals the Sustained Cognitive Benefits of Milk Fat Globule Membrane (MFGM) Photo download: Link HONG KONG, Sept. 16, 2025 /PRNewswire/ -- Mead Johnson Nutrition Hong Kong ("Mead Johnson"), in collaboration with Medical Conscience, hosted a Paediatric Nutrition Symposium on September 15. The Symposium, themed "Clinical Benefits of Milk Fat Globule Membrane (MFGM) for Sustained Neurodevelopment at Age...
ALCOR Scientific Transforms ESR Testing: Extends Blood Sample Stability from 4 to 28 Hours
Diagnostic Company's iSED Analyzers Deliver Seven-Fold Stability Increase to Improve Accuracy, Efficiency, and Patient Care SMITHFIELD, R.I., Sept. 16, 2025 /PRNewswire/ -- ALCOR Scientific today announced a breakthrough in erythrocyte sedimentation rate (ESR) testing that solves one of the most persistent challenges facing modern laboratories: limited blood sample stability. The global diagnostic provider's family of iSED ESR analyzers leverage novel technology...
ShiraTronics Announces Positive 12-Month Follow-Up Results from RELIEV-CM Pilot Study, Demonstrating Sustained Clinical Benefit with Investigational Implantable Neuromodulation Therapy for Chronic Migraine
MINNEAPOLIS, Sept. 16, 2025 /PRNewswire/ -- ShiraTronics, Inc., a clinical-stage medical device company focused on developing novel neuromodulation therapies for chronic migraine, today announced compelling 12-month follow-up data from its RELIEV-CM Pilot Study. The findings demonstrate sustained reductions in headache frequency and severity, continued improvement in migraine-specific quality of life, and...
LA MER DOUBLES DOWN ON MIRACLE BROTH™ WITH NEW BIOENERGETICS RESEARCH PLATFORM AND LANDMARK PARTNERSHIP WITH THE SALK INSTITUTE
THE PLATFORM LAUNCHES WITH 'LA MER GIVES SKIN LIFE' CAMPAIGN & A THREE-YEAR HEALTHY AGING FELLOWSHIP HONG KONG, Sept. 16, 2025 /PRNewswire/ -- La Mer has long been known to provide skin with cellular energy and has remained dedicated to exploring the bioenergetic efficacy of Miracle Broth, from sea to skin. Building on over 50 years of scientific...
Celebrating Cross-Border Partnerships in Healthcare, Asia Medical Week 2025 Convened Leaders in Bali to Strengthen Excellence and Preparedness
BALI, Indonesia, Sept. 16, 2025 /PRNewswire/ -- The Asia Medical Week (AMW) and the Asia Medical Innovation and Development Forum 2025 officially took place from September 12-13 in Bali with a mission to bring together healthcare leaders from across Asia to strengthen cross-border collaboration and resilience. As a supporting partner, Mindray (300760.SZ), a global leader in medical devices and...
Globally Significant Opportunity Emerges as Remplir™ is used in Nerve-Sparing Prostate Cancer Surgery
Potential to reduce the risk of erectile dysfunction and urinary incontinence PERTH, Australia, Sept. 16, 2025 /PRNewswire/ -- Regenerative medicine company Orthocell Limited (ASX:OCC, "Orthocell" or the "Company") is pleased to announce its flagship nerve repair device, Remplir, has been introduced to Urologists in Australia for use in nerve-sparing Robotic-Assisted Radical Prostatectomies (RARP). Remplir has been used in approximately 40...
Akeso’s Ligufalimab (CD47 mAb) Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia (AML)
HONG KONG, Sept. 16, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) today announced that its proprietary next-generation humanized IgG4 monoclonal antibody targeting CD47, ligufalimab (AK117), has been granted Orphan Drug Designation (ODD) by the U.S. FDA for the treatment of acute myeloid leukemia (AML). The Orphan Drug Designation is a program established by the FDA to incentivize the development...
Chulalongkorn Bariatric and Metabolic Institute (Chula BMI), a One-Stop Service Center for Holistic Obesity Treatment
BANGKOK, Sept. 16, 2025 /PRNewswire/ -- Say goodbye to obesity with the Chulalongkorn Bariatric and Metabolic Institute (Chula BMI)—King Chulalongkorn Memorial Hospital's one-stop center for comprehensive, holistic obesity care. A team of doctors and multidisciplinary specialists, including experts in medicine, surgery, nutrition, and behavioral therapy, is now ready to provide patients with guidance on preventing obesity before it's too late....
Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the 34th EADV Congress 2025
SAN FRANCISCO and SUZHOU, China, Sept. 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, announces that it will present multiple research results at the 34th European Academy of Dermatology and Venereology (EADV) Congress...
